Journal of Asthma and Allergy最新文献

{"title":"Fructose-Bisphosphate Aldolase Mediating Pollen-Food Allergy Syndrome.","authors":"Lisha Li, Junda Li, Kai Guan","doi":"10.2147/JAA.S493295","DOIUrl":"10.2147/JAA.S493295","url":null,"abstract":"<p><p>Pollen-food allergy syndrome is an IgE-mediated allergic reaction arising from cross-reactive homologous allergens found in both food and pollen. Allergens, such as pathogenesis-related protein class 10 and profilin, usually trigger oropharyngeal itching and numbness in patients, whereas lipid transfer proteins tend to induce anaphylaxis. This article presents a case study of an individual with Artemisia pollen allergy who experienced anaphylaxis after consuming red fruit ginseng, a perennial herb belonging to the Campanulaceae family. This study revealed a novel allergen component mediating cross-allergy between Artemisia pollen and food, fructose-bisphosphate aldolase, which has not been documented in the literature concerning the pollen-food allergy syndrome. Fructose-bisphosphate aldolase tends to induce anaphylaxis in patients with Artemisia pollen-allergy and warrants clinicians' attention.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"17 ","pages":"1287-1290"},"PeriodicalIF":3.7,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11653883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcome of Childhood Asthma: Characterizing COPD-A and COPD-C Subtypes in Adulthood.","authors":"Osman Savran, Klaus Bønnelykke, Charlotte Suppli Ulrik","doi":"10.2147/JAA.S474417","DOIUrl":"10.2147/JAA.S474417","url":null,"abstract":"<p><strong>Background and aim: </strong>Asthma in early life has been linked to subsequent development of COPD and according to GOLD 2023 COPD may be divided into distinct subtypes. We aimed to investigate factors associated with the GOLD classification COPD-A (asthma in childhood) and COPD-C (tobacco exposure) in a cohort of adults with a history of severe childhood asthma.</p><p><strong>Patients and methods: </strong>In a cohort of Danish adults with a history of severe childhood asthma and a previous 4-month stay during childhood at the asthma care facility in Kongsberg, Norway, we divided participants in a long-term follow-up examination into COPD-A and COPD-C, defined as post-bronchodilator FEV₁/FVC < 0.7, and never-smoker or ever-smoker, respectively, and no airflow limitation. Characteristics between groups were analysed.</p><p><strong>Results: </strong>The study cohort comprised 232 adults with a history of severe childhood asthma, of whom 30 (13%) and 23 (10%), respectively, were classified as COPD-A and COPD-C. Compared to those with no airflow limitation, individuals with COPD-A and COPD-C more often had had at least one exacerbation (filled prescription of oral corticosteroid) in the past 12 months (risk ratio [RR] 1.83 and 2.65, respectively). The COPD-C group had a significantly higher Medical Research Council dyspnoea score (p<0.01) and significantly higher blood eosinophil count (p<0.01) than those with no airflow limitation. Compared to the COPD-C group, the COPD-A group had higher fractional exhaled nitric oxide (mean 29 [SD 28]) and FEV₁%pred (mean 75 [SD 20]). Finally, when comparing participants with COPD-A to both COPD-C and participants without airflow limitation, the proportion of participants with osteoporosis (17%) and depression (10%) was more than twice as high.</p><p><strong>Conclusion: </strong>Our study revealed a high prevalence and unique features of the two COPD subtypes COPD-A and COPD-C in a cohort of adults with a history of severe childhood asthma.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"17 ","pages":"1291-1300"},"PeriodicalIF":3.7,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11653850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Trends and Hotspots on Asthma and Depression: A Bibliometric Analysis.","authors":"Guoran Peng, Beibei Cheng, Rongzhen Ding, Aiguo Dai","doi":"10.2147/JAA.S495814","DOIUrl":"10.2147/JAA.S495814","url":null,"abstract":"<p><strong>Purpose: </strong>Asthma and depression are prevalent conditions with significant comorbidity, impacting patients' quality of life. This bibliometric study aims to analyze research trends and hotspots in the field from 2000 to 2023, identifying key contributions and predicting future directions.</p><p><strong>Methods: </strong>We conducted a systematic search in the Web of Science Core Collection (WoSCC) for articles on asthma and depression, published between 2000 and 2023. Bibliometrics, which involves the application of mathematical and statistical methods to analyze scholarly literature, was employed in this study to systematically assess the research trends and hotspots in the field of asthma and depression. VOSviewer and CiteSpace software were utilized for visual analysis and data visualization, enabling us to map collaboration networks and identify research hotspots and trends within the asthma and depression literature.</p><p><strong>Results: </strong>Our analysis retrieved 3067 papers from 937 journals, involving 14,631 authors and 4006 institutions across 106 countries. The United States, Columbia University, the Journal of Asthma, and Christer Janson were the most prolific contributors. Six primary research themes emerged: quality of life, childhood asthma, primary care, substance P, intervention, and emotion. Additionally, Burst detection analysis identified emerging topics, including severe asthma, other respiratory diseases, and oxidative stress.</p><p><strong>Conclusion: </strong>This bibliometric analysis has revealed significant insights into the research trends and hotspots in the field of asthma and depression. The primary findings indicate a growing body of research highlighting the impact of depression on asthma control and patients' quality of life, the need for psychological interventions in treating comorbid asthma and depression, and the emerging focus on severe asthma and oxidative stress mechanisms. These findings underscore the importance of continued research in these areas to advance our understanding and improve clinical outcomes for patients with these comorbid conditions.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"17 ","pages":"1271-1285"},"PeriodicalIF":3.7,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11648539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142835742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possible Biological Heterogeneity of Airway Mucus Plugs in a Patient with Asthma.","authors":"Hiroki Tashiro, Mizuki Nanri, Yuki Kuwahara, Yuki Kurihara, Shinya Kimura, Koichiro Takahashi","doi":"10.2147/JAA.S499026","DOIUrl":"10.2147/JAA.S499026","url":null,"abstract":"<p><strong>Background: </strong>The presence of mucus plugs in the airway is a severe phenotype in patients with asthma; however, the mechanisms and specific treatments are not fully understood.</p><p><strong>Purpose: </strong>To clarify the efficacy of biologics and the mechanisms for mucus plug in patients with asthma.</p><p><strong>Patients and methods: </strong>A 79-year-old Japanese asthmatic woman with high blood eosinophil and fractional exhaled nitric oxide (FeNO) was pointed massive mucus plugs in airway on chest CT imaging. She was treated with mepolizumab for 3 months; however, those were augmented without improvement of pulmonary function and FeNO. She was switched to dupilumab and, three months later, the mucus plugs were completely disappeared with improvement in pulmonary function, FeNO and asthma-related symptoms. She continues treatment with dupilumab, and her asthma symptoms are stable.</p><p><strong>Conclusion: </strong>Biologics including mepolizumab and dupilumab have been reported to improve mucus plugs in patients with asthma; however, their efficacy might be different depending on the clinical characteristics of patients. Present data remind us of the possibility that, if FeNO levels remain high after treatment with anti-IL-5 antibody in asthma patients with mucus plugs, switching to other biologics, including anti-IL-4Rα antibody, might be considered.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"17 ","pages":"1265-1269"},"PeriodicalIF":3.7,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11628187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent Refractory Atopic Dermatitis and Generalized Vitiligo Successfully Treated with Abrocitinib: A Case Report.","authors":"Xinyi Shao, Xingyu Pan, Yangmei Chen, Yan Zhu, Shuang Chen, Jin Chen","doi":"10.2147/JAA.S492614","DOIUrl":"10.2147/JAA.S492614","url":null,"abstract":"<p><p>Atopic dermatitis (AD) may sometimes be comorbid with vitiligo. However, these therapeutic agents are often slow acting and lead to various adverse effects, resulting in poor patient compliance. This report describes a 65-year-old male patient with refractory moderate-to-severe atopic dermatitis (AD) and generalized vitiligo. The patient was treated with repeated antihistamine and dupilumab injections; however, erythema and pruritus did not improve. Consequently, oral abrocitinib was administered to treat AD and vitiligo, and the patient's generalized erythema, papules, and pruritus ameliorated with the repigmentation of vitiligo lesions. This case provided evidence of the efficacy and safety of oral abrocitinib for patients with concurrent refractory AD and vitiligo.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"17 ","pages":"1259-1263"},"PeriodicalIF":3.7,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11624682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Exercise Capacity in Patients Diagnosed with Moderate and Severe Bronchial Asthma: Preliminary Prospective Observational Study.","authors":"Weronika Alicja Bajer, Marta Majewska-Pulsakowska, Małgorzata Paprocka-Borowicz, Krzysztof Wytrychowski, Jakub Taradaj, Kuba Ptaszkowski","doi":"10.2147/JAA.S458717","DOIUrl":"10.2147/JAA.S458717","url":null,"abstract":"<p><strong>Purpose: </strong>The main objective of the study was to assess exercise capacity and physical activity levels in patients with bronchial asthma compared to a control group without asthma, as well as to investigate how asthma severity affects the results of the 6MWT and physical activity as measured by the IPAQ questionnaire.</p><p><strong>Patients and methods: </strong>A total of 63 individuals were studied, divided into two groups: Group A, consisting of 33 individuals with bronchial asthma, and Group B, consisting of 30 individuals from the general population without bronchial asthma. In both groups, the following assessments were performed: The Six-Minute Walk Test (6MWT), The International Physical Activity Questionnaire (IPAQ) and the Borg rating of perceived exertion scale (the Borg RPE scale) ABB.</p><p><strong>Results: </strong>It was demonstrated that patients with moderate asthma covered more distance during the 6MWT than patients diagnosed with severe asthma. The difference in metres covered between the two groups was statistically significant (p < 0.001), which could be observed during the walk test. The results indicate that a larger proportion of patients with asthma (76%) fall into the insufficient physical activity category compared to those without asthma (24%). Conversely, a higher percentage of non-asthmatic individuals (66.67%) report sufficient physical activity compared to asthmatic patients (33.33%)(P=0.005).</p><p><strong>Conclusion: </strong>This study demonstrated that asthma severity significantly impacts exercise capacity, as shown by shorter distances covered in the 6-minute walk test (6MWT) among patients with severe asthma. While overall physical activity levels (measured by the IPAQ) were not significantly different between asthma and non-asthma groups, asthma patients exhibited significantly more sitting time, suggesting a more sedentary lifestyle.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"17 ","pages":"1247-1258"},"PeriodicalIF":3.7,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11624687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Series of Patients Undergoing Bronchial Thermoplasty a Second Time for Severe Asthma.","authors":"Chuan T Foo, David Langton, Francis Thien","doi":"10.2147/JAA.S492730","DOIUrl":"10.2147/JAA.S492730","url":null,"abstract":"<p><p>Bronchial thermoplasty is a treatment option for patients with severe asthma. We report a case series of 6 patients who underwent bronchial thermoplasty on two separate occasions for poorly controlled asthma. The repeat procedures were well tolerated with no unexpected complications. One patient developed a focal area of mild bronchiectasis on imaging 6-months after repeat treatment, but this was not felt to be clinically relevant. Individual responses to repeat bronchial thermoplasty were varied, with some patients showing great improvement after treatment, whereas others did not. This series highlights the safety and feasibility of performing repeat ablation on previously ablated airways, as well as the potential clinical benefit in a select group of patients.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"17 ","pages":"1239-1245"},"PeriodicalIF":3.7,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers Reflecting the Severity of Bronchial Asthma in Children.","authors":"Peter Kunc, Michal Pokusa, Dominika Hajduchova, Jaroslav Fabry, Marek Samec, Martina Neuschlova, Renata Pecova","doi":"10.2147/JAA.S486958","DOIUrl":"10.2147/JAA.S486958","url":null,"abstract":"<p><strong>Background: </strong>Bronchial asthma, the most prevalent chronic inflammatory airway disease in children, exhibits a concerning rise in both incidence and prevalence. Asthma biomarkers hold promise for stratifying patients into distinct clinical phenotypes, paving the way for targeted and personalized treatment approaches.</p><p><strong>Aim of study: </strong>This study aimed to evaluate the association between novel and non-established semi-invasive circulating and well-known exhaled inflammatory biomarkers in two distinct pediatric asthma populations stratified by disease severity.</p><p><strong>Materials and methods: </strong>Forty-four asthmatic children aged 8-12 years meeting inclusion criteria were recruited from hospitalized patients. The first group (n=15, mean age 9.8 years) consisted of patients with mild persistent asthma who did not require regular inhaled corticosteroids (ICS). The second group (n=29, mean age 9.8 years) consisted of children with moderate to persistent asthma who received regular ICS treatment. Serum levels of interleukins (IL-13, IL-1β), eosinophil-derived neurotoxin (EDN), and surfactant protein D (SPD) were measured by ELISA in all participants. In addition, exhaled nitric oxide (FeNO) and blood eosinophil counts were evaluated.</p><p><strong>Results: </strong>No significant differences were observed in the baseline plasma concentrations of inflammatory markers (IL-13, IL-1β, SPD, and EDN) or exhaled FeNO between the ICS-treated and non-ICS-treated groups. Further inter-individual analysis confirmed significant positive correlations between IL-13, SPD, and IL-1β (Pearson's r = 0.591-0.781) in both groups of patients. Interestingly, the ICS-treated group compared to the nontreated group showed an exclusive moderate negative correlation between FeNO and IL-1β. In contrast, FeNO exhibited a positive correlation with EDN and a strong association with eosinophil count in all the study groups.</p><p><strong>Conclusion: </strong>Our findings highlight the complex and unresolved role of asthma biomarkers in routine clinical practice for the management of childhood asthma, particularly in predicting exacerbations. By comparing the relationships of carefully selected biomarkers, we can achieve a greater clinical predictive value.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"17 ","pages":"1227-1237"},"PeriodicalIF":3.7,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delving into Uncontrolled or Severe Asthma: Perspectives from Patients and Healthcare Professionals in a Cross-Sectional Study.","authors":"Eleonora Volpato, Vincenzo Pennisi, Alfio Pennisi, Alessio Piraino, Paolo I Banfi, Salvatore D'Antonio, Stefano Centanni, Luca Cavalieri, Mattia Ramaccia, Filomena Bugliaro, Simona Barbaglia, Antonietta Cappuccio, Roberta Termini, Maria Giulia Marini","doi":"10.2147/JAA.S483020","DOIUrl":"10.2147/JAA.S483020","url":null,"abstract":"<p><strong>Background: </strong>Despite the effectiveness of inhalation therapy, uncontrolled or severe asthma remains prevalent challenges in respiratory care Narrative Medicine (NM) offers a linguistic approach to comprehending illness experiences, thereby providing a framework for advancing healthcare.</p><p><strong>Aim: </strong>The primary aim of this study was to gather narratives from individuals grappling with severe or uncontrolled asthma and their Healthcare Professionals (HCPs), in order to explore the intricate interplay among quality of care, quality of life, psychological and social determinants, and adherence patterns.</p><p><strong>Methods: </strong>A cross-sectional NM study was conducted in Italy from February to December 2023, encompassing 135 patients with uncontrolled or severe asthma (54.7% male; mean age: 56.7 years) and 47 HCPs (64.9% male; mean age: 54.3 years). A mixed-method approach was adopted to scrutinize themes, language nuances, emotional expressions, and narrative classifications.</p><p><strong>Results: </strong>Patients with uncontrolled or severe asthma reported an average illness duration of 4.46 years, with exacerbations occurring over the past 20.9 months. Pulmonologists (83% of HCPs) played a predominant role in diagnosing and treating the disease in 96.1% of patients. Additionally, participants with severe asthma reported higher healthcare needs. The most reported emotions were fatigue (25.96%) and a sense of suffocation (11.53%). Upon commencing treatment, while experiencing physical improvement, patients predominantly expressed feelings of \"submission/dependence\" on medication (28%), followed by \"fear\" (21%) and \"serenity/joy\" (21%). HCPs, primarily pulmonologists (83%), emphasized the importance of raising awareness among specialists and General Practitioners (GPs), disseminating information, optimizing prescriptions, implementing phenotyping, tailoring therapy, and considering paediatric needs.</p><p><strong>Conclusion: </strong>These findings contribute to a deeper understanding of patient perspectives, facilitate personalized interventions, and underscore the factors influencing therapeutic adherence in uncontrolled or severe asthma.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"17 ","pages":"1207-1226"},"PeriodicalIF":3.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11603902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of Childhood Asthma in the UK.","authors":"Imène Gouia, Florence Joulain, Yi Zhang, Christopher Ll Morgan, Asif H Khan","doi":"10.2147/JAA.S452741","DOIUrl":"10.2147/JAA.S452741","url":null,"abstract":"<p><strong>Purpose: </strong>Global prevalence of pediatric asthma and associated morbidity and mortality has continuously increased. Asthma is the most common chronic illness in children in the UK; however, recent epidemiology data are lacking. This analysis describes the overall prevalence and burden of illness of asthma in children.</p><p><strong>Methods: </strong>This was a retrospective, longitudinal, database analysis using the Clinical Practice Research Datalink database. Primary care records of 19,330 patients (6-11 years) between January 1 and December 31, 2017, were analyzed. Asthma prevalence was assessed by severity (as described by Global Initiative for Asthma 2017 guidelines), and symptoms, comorbidities, and treatments were compared between asthma patients and matched non-asthmatic controls. Results are presented descriptively; logistic regression analyses were performed for asthma symptoms.</p><p><strong>Results: </strong>The estimated prevalence of pediatric asthma was 6.5% (95% CI: 6.4-6.5) in the UK (mild: 74.2%; moderate: 15.0%; severe: 10.8%). All patients with moderate or severe asthma and 72.5% of patients with mild asthma were prescribed drug therapy. Most patients with moderate or severe asthma were prescribed a short-acting β2-agonist (94.9% and 96.0%, respectively), compared with 69.2% of mild asthma patients. Daytime symptoms were reported by 78.1% in those with severe asthma; 34.9% reported night-time symptoms and 30.8% reported an impact on usual activities. Asthma patients had a higher baseline prevalence of comorbidities compared with non-asthmatic controls, notably atopic dermatitis (47.8% in severe asthma versus 20.8% in controls) and allergic rhinitis (13.3% in severe asthma versus 2.0% in controls).</p><p><strong>Conclusion: </strong>This analysis confirmed that asthma remains a common morbidity among children in the UK. Increasing asthma severity was associated with worsening symptoms, and asthma patients had significantly more comorbidities compared with non-asthmatic controls.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"17 ","pages":"1197-1205"},"PeriodicalIF":3.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}